Abstract
Abstract
Background
The goal of this work was to determine the quantitative accuracy and optimal reconstruction parameters for 124I-PET imaging in the presence of therapeutic levels of 131I. In this effort, images were acquired on a GE D710 PET/CT scanner using a NEMA IEC phantom with spheres containing 124I and increasing amounts of 131I activity in the background. At each activity level, two scans were acquired, one with the phantom centered in the field of view (FOV) and one 11.2 cm off-center. Reconstructions used an ordered subset expectation maximization algorithm with up to 100 iterations of 16 subsets, with and without time-of-flight (TOF) information. Results were evaluated visually and by comparing the 124I activity relative to the scan performed in the absence of 131I.
Results
131I within the FOV added to the randoms rate, to dead time, and to pile-up within the detectors. Using our standard clinical reconstruction parameters, the image quality and quantitative accuracy suffered at 131I activities above 1.4 GBq. Convergence rates slowed progressively in the presence of increasing amounts of 131I for both TOF and nonTOF reconstructions. TOF reconstructions converged more quickly than nonTOF but often towards erroneous concentrations. Iterating nonTOF reconstructions to convergence produced quantitatively accurate images except for the off-center phantom at the very highest level of background 131I tested.
Conclusions
This study shows that quantitative PET is feasible in the presence of large amounts of 131I. The high randoms fractions resulted in slow reconstruction convergence and negatively impacted TOF corrections and/or the accuracy of TOF information. Therefore, increased iterations and nonTOF reconstructions are recommended.
Funder
National Institutes of Health
Publisher
Springer Science and Business Media LLC
Subject
Radiology Nuclear Medicine and imaging,Instrumentation,Biomedical Engineering,Radiation
Reference13 articles.
1. Sgouros G, Hobbs RF, Atkins FB, Van Nostrand D, Ladenson PW, Wahl RL. Three-dimensional radiobiological dosimetry (3D-RD) with I-124 PET for I-131 therapy of thyroid cancer. Eur J Nucl Med Mol Imaging. 2011;38(S1):41–7. https://doi.org/10.1007/s00259-011-1769-1.
2. Kolbert KS, Pentlow KS, Pearson JR, Sheikh A, Finn RD, Humm JL, et al. Prediction of absorbed dose to normal organs in thyroid cancer patients treated with 131I by use of 124I PET and 3-dimensional internal dosimetry software. J Nucl Med. 2007;48:143–9.
3. Kreissl MC, Janssen MJR, Nagarajah J. Current treatment strategies in metastasized differentiated thyroid cancer. J Nucl Med. 2019;60(1):9–15. https://doi.org/10.2967/jnumed.117.190819.
4. Huang SY, Bolch WE, Lee C, Van Brocklin HF, Pampaloni MH, Hawkins RA, et al. Patient-specific dosimetry using pretherapy [(1)(2)(4)I]m-iodobenzylguanidine ([(1)(2)(4)I]mIBG) dynamic PET/CT imaging before [(1)(3)(1)I]mIBG targeted radionuclide therapy for neuroblastoma. Mol Imaging Biol. 2015;17(2):284–94. https://doi.org/10.1007/s11307-014-0783-7.
5. Freudenberg LS, Jentzen W, Stahl A, Bockisch A, Rosenbaum-Krumme SJ. Clinical applications of 124I-PET/CT in patients with differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2011;38(Suppl 1):S48–56. https://doi.org/10.1007/s00259-011-1773-5.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献